DoMore Diagnostics, Proscia Ink Collaboration on Colorectal Cancer Histopathology Testing

NEW YORK – Digital pathology firms DoMore Diagnostics and Proscia said Wednesday that they are collaborating on combining their respective technologies to help pathologists predict outcomes for colorectal cancer patients and incorporate artificial intelligence-assisted decision support into routine pathology workflows.

The firms said they will integrate Oslo, Norway-based DoMore's Histotype Px Colorectal digital biomarker and Philadelphia-based Proscia's Concentriq Dx digital pathology platform. Histotype Px is CE-marked under IVDD rules and available for research use outside the European Union, while Concentriq Dx is CE-marked under IVDR rules.

DoMore CEO Torbjørn Furuseth said in a statement that recent study results showed Histotype Px Colorectal can offer valuable insights, guide personalized treatment decisions, and help improve patient outcomes.

"We must now continue to integrate the algorithm into pathologists' routine operations for it to make the greatest impact," he said. "As leading laboratories are increasingly turning to Proscia, our partnership paves the way for accelerating its adoption."

Stephan Fromme, Proscia's head of strategic alliances, said in a statement that laboratories are increasingly demanding open pathology applications like Concentriq Dx, which can integrate AI applications from Proscia, Proscia's customers, and third parties such as DoMore into routine workflows.

"They recognize that unlocking more utility for pathologists and patients means tapping into the collective power of a growing number of solutions," he said. "We look forward to adding Histotype Px Colorectal to our ecosystem to help our users make increasingly personalized diagnoses that can ultimately reduce overtreatment for more patients."

Proscia also inked a multiyear distribution deal earlier this year with Agilent Technologies to offer Proscia's Concentriq Dx platform.